Key result
Clevidipine provided superior blood pressure control in acute hypertension and significantly reduced mortality compared with sodium nitroprusside (1.7% vs 4.7%).
Why the study?
Does clevidipine improve blood pressure control in patients with acute hypertension?
Does clevidipine improve blood pressure control in patients with acute hypertension?
Clevidipine is an effective ultra-short-acting calcium channel blocker for the rapid management of acute hypertension, showing superiority in blood pressure control and potentially mortality compared to traditional agents.
Answers are grounded in this paper and cite their sources.
May support clevidipine in acute hypertension; leaves open need for randomized confirmation.
Clevidipine is a new ultra-short-acting calcium channel blocker of the dihydropiridine class. It is characterized by its vascular selectivity, extremely high clearance value and a small volume of distribution that together result in an extremely short half-life of approximately 1 min, thus allowing the rapid titration to the desired effect. In recent studies, the ESCAPE 1, ESCAPE 2, ECLIPSE and VELOCITY trials, clevidipine has shown a clear advantage in the management of acute hypertension when compared with placebo, as evidenced in ESCAPE 1 and 2. In the VELOCITY trial, clevidipine demonstrated a reduction in blood pressure of 6% at the 3-min mark, 15% within 9.5 min and 27% at the 18-h mark. The ECLIPSE trial compared clevidipine to sodium nitroprusside, nitroglycerin and nicarpidine. Clevidipine was demonstrated to be superior to the other agents in providing blood pressure control, and also provided a significant reduction in mortality when compared with nitroprusside (1.7 vs 4.7%).
No takes yet. Share an insight, caveat, or question.
Varón et al. (2008) conducted a review in acute hypertension. Clevidipine vs. placebo, sodium nitroprusside, nitroglycerin, nicarpidine was evaluated on mortality. Clevidipine provided superior blood pressure control in acute hypertension and significantly reduced mortality compared with sodium nitroprusside (1.7% vs 4.7%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: